洛铂联合方案治疗晚期无EGFR敏感突变非小细胞肺癌的临床观察

Clinical observation of combination regimen contains lobaplatin for no sensitive EGFR mutations of advanced nonsmall cell lung cancer

目的:观察洛铂联合化疗方案治疗晚期无EGFR敏感突变非小细胞肺癌的疗效及毒副反应。方法:随机选择2015年1月至2017年1月到我院进行治疗的32例期非小细胞肺癌患治疗为研究背景。采用含洛铂(30mg/m^(2))与西紫杉醇以及紫杉醇实施治疗,治疗周期设定为2周期,一周期包含3-4周,且在实施治疗后的2周对患者的各项系数进行评价分析。结果:患者实施治疗后,可评价疗程与毒副反应效果均良好。其中CR患者不选在,有4例SD患者,8例PD患者,有效率为62.5%,疾病控制率达到了75%。肺腺癌(DCR73.3%)与肺鳞癌(DCR75%)、未分类肺癌(DCR77.8%)比较,差异无统计学意义(P>0.05)。洛铂联合多西紫杉醇(DCR75%)与联合紫杉醇组(DCR75%)比较,差异无统计学意义(P>0.05)。一线方案治疗(DCR78.6%)与二线及以上方案(DCR72.2%)比较差异无统计学意义(P>0.05)。至随访截止日期,21例患者疾病进展,中位无疾病进展生存期为5个月。其中患者出现的毒副作用体现为消化道反应与骨髓抑制以及疲乏等方面,一般程度为1、2级,通过相对处理后患者均无大碍、无死亡情况。结论:洛铂联合多西紫杉醇或紫杉醇方案治疗晚期无EGFR敏感突变非小细胞肺癌疗效较好,毒副反应可耐受。

Objective:T Objective To observe the efficacy and toxicity of lobaplatin combined with chemotherapy in the treatment of advanced non-small cell lung cancer without EGFR sensitive mutation.Methods:From January 2015 to January 2017,32 patients with no sensitive EGFR mutations of advanced nonsmall cell lung cancer were enrolled in this study.obaplatin(30mg/m^(2))combined with docetaxel or paclitaxel were given to patients hree four weeks was a cycle he efficacy and side efects were evaluated after at least two cycles of chemotherapy Results:Therapeutic efficacy and adverse reactions could be evaluated in all patients with n0 CR patient,0 cases of PR,cases of SD and 8 cases of PD.The response rate(RR)was 62.5% and the disease control rate(DCR)was 75%here was no significant difference in DCR between 1ung adenocarcinoma(DCR733%),squamous cell carcinoma(DCR75%)and unclassified lung cancer(DCR77.8%)(P>0.05).There was no significant difference in DCR between docetaxel group(DCR75%)and paclitaxel group(DCR75%)(P>0.05).There was no significant difference in DCR between first-line regimen(DCR786%)and second-line regimen(DCR72.2%)(P>0.05).Iwenty-one patients had progressed atthe deadline ffollowrup.edian progression-free survival time was 5months(95%CI:3.94-6.05 months).The main side effects were myelosuppression atigue and gastrointestinal reaction,which were mosty in grade 1-2 and alleviated by symptomatic treatment.Conclusion:Lobaplatin combined with docetaxel or paclitaxe1 for no sensitive EGFR mutations of advanced nonsmall cell lung cancer is effectire and well tolerated.